Alere

Alere was a United States-based healthcare diagnostics company whose principal business was the development, manufacture, and commercialization of rapid point-of-care tests. The company was founded in 1991 by Ron Zwanziger as SelfCare and later became associated with the names Inverness Medical Technology and Inverness Medical Innovations before adopting the Alere name in 2010. It became a publicly traded company in the 1990s and expanded substantially through acquisitions across infectious-disease testing, cardiometabolic diagnostics, toxicology, molecular diagnostics, and consumer health testing. The company’s core proposition was to move selected diagnostic procedures closer to the patient. Instead of requiring every sample to be sent to a centralized laboratory, Alere supplied instruments, reagents, and rapid tests for use in hospitals, clinics, pharmacies, physician offices, emergency settings, public-health programs, and homes. Its portfolio addressed three broad areas: cardiometabolic testing, infectious-disease testing, and toxicology. It also offered consumer diagnostic products through a joint venture with Procter & Gamble, including products marketed under the Clearblue name. Alere’s expansion strategy relied in part on acquisitions. Its acquired businesses and technologies included Unipath, Clondiag, Ionian Technologies, TwistDx, Wampole Laboratories, Ostex International, Binax, Biosite, HemoSense, Cholestech, Redwood Toxicology, Concateno, BBI Holdings, eScreen, Standard Diagnostics, and Axis-Shield-related assets. The acquisitions gave Alere access to pregnancy testing, infectious-disease assays, molecular platforms, diabetes and cardiometabolic testing, toxicology services, and international distribution capabilities. The company introduced several notable products and platforms. Clearblue Digital was described as the first digital pregnancy test. The Alere CD4 analyser was designed to provide absolute CD4 results at the point of care, supporting HIV patient management. The Alere i platform brought rapid molecular testing into near-patient settings, with assays for influenza, group A streptococcal infection, and respiratory syncytial virus. The Alere q HIV analyser extended nucleic-acid testing into decentralized healthcare environments. Alere also faced regulatory and legal scrutiny. In 2012, the United States Food and Drug Administration issued a warning concerning the company’s response to earlier observations about manufacturing processes associated with Triage products. In 2016, the United States Department of Justice began investigating potential Medicaid and Medicare fraud involving Alere. These matters formed part of the company’s late-period operating and compliance challenges. Abbott Laboratories announced an agreement to acquire Alere in 2016. The transaction became contentious when Abbott later sought to terminate the deal, a request rejected by Alere’s board. The parties ultimately completed the acquisition on October 3, 2017, at a reduced transaction value. Alere ceased to exist as an independent public company, and its operations, products, and subsidiaries were incorporated into Abbott’s diagnostics organization. The Alere corporate brand is therefore principally historical, although some technologies and product capabilities continued within Abbott’s broader diagnostic portfolio.

Alere began in 1991 when Ron Zwanziger founded SelfCare in the United States. The business entered the public markets in 1996 and changed its name to Inverness Medical Technology in 2000. In 2001, it sold its diabetes business to Johnson & Johnson and separated a new company, Inverness Medical Innovations, which became the principal vehicle for later expansion. Inverness Medical Innovations pursued a broad acquisition program. The company added businesses and technologies associated with consumer pregnancy testing, infectious diseases, molecular diagnostics, cardiometabolic testing, toxicology, and laboratory workflow. Among the companies and assets associated with this expansion were Unipath, Clondiag, Ionian Technologies, TwistDx, Wampole Laboratories, Ostex International, Binax, Biosite, HemoSense, Cholestech, Redwood Toxicology, Concateno, BBI Holdings, eScreen, Standard Diagnostics, and Axis-Shield-related operations. This portfolio gave the company a presence across both professional and consumer testing. In 2007, the company formed Swiss Precision Diagnostics with Procter & Gamble to sell and market consumer diagnostic products. The venture supported the consumer-facing side of the business, while Alere’s main corporate strategy increasingly emphasized decentralized medical testing. In 2010, Inverness Medical Innovations changed its name to Alere and adopted the ALR ticker on the New York Stock Exchange. The rebranding presented the company as a diagnostics-focused organization rather than a collection of acquired businesses. Alere’s operating model centered on point-of-care testing. Its products were intended to provide results in hospitals, clinics, physician offices, pharmacies, emergency departments, public-health settings, and homes without relying entirely on distant central laboratories. The company organized its activities around cardiometabolic, infectious-disease, and toxicology testing. It also developed or acquired molecular technologies intended to bring nucleic-acid testing to smaller and more decentralized care environments. The company’s product development included several notable milestones. Clearblue Digital was presented as the first digital pregnancy test. The Alere CD4 analyser was designed to produce absolute CD4 counts at the point of care, an important capability for HIV care in settings where conventional laboratory infrastructure could be limited. The Alere i platform supported rapid molecular testing for influenza and group A streptococcal infection, while later regulatory clearances extended the platform to respiratory syncytial virus. The Alere q HIV analyser was designed as an automated nucleic-acid testing system suitable for use nearer to patients. Alere also encountered regulatory difficulties. In 2012, the FDA issued a warning related to the company’s response to prior observations about manufacturing processes for Triage products. In 2016, the United States Department of Justice opened an investigation into potential Medicaid and Medicare fraud involving the company. These developments added compliance and reputational pressure during a period when Alere was also managing portfolio changes and strategic uncertainty. In 2014, Zwanziger resigned as chief executive. Namal Nawana, previously the company’s chief operating officer, first served as interim CEO and was appointed permanent CEO later that year. Zwanziger subsequently offered to take the company private. In 2015, Alere divested its Alere Health management activities to Optum, narrowing its activities around diagnostics. Abbott Laboratories announced an agreement to acquire Alere in February 2016. The proposed transaction later became contentious: Abbott asked that the deal be terminated, but Alere’s board rejected that request. The parties ultimately renegotiated the transaction, and Abbott completed the acquisition on October 3, 2017, at a reduced price. The acquisition also brought Arriva Medical, a mail-order diabetes supplier, into Abbott’s ownership. Alere’s independent public-company identity ended, and its businesses were absorbed into Abbott’s diagnostics operations. As a result, Alere is now best understood as a historical corporate brand and former diagnostics company rather than an active independent enterprise.

1. 2017Abbott completes the acquisition

   Abbott completed the acquisition on October 3, 2017, ending Alere’s status as an independent public company.

   Source
2. 2016Abbott announces acquisition agreement

   Abbott Laboratories announced an agreement to acquire Alere, beginning a transaction that was later renegotiated.

   Source
3. 2016Alere i RSV test receives FDA clearance

   The FDA cleared the Alere i RSV Rapid Molecular Test, designed to detect respiratory syncytial virus in approximately 13 minutes or less.

   Source
4. 2015Alere Health activities are divested

   Alere sold its Alere Health management activities to Optum.

   Source
5. 2015Alere q HIV analyser receives CE marking

   The Alere q HIV analyser received IVD CE marking as an automated nucleic-acid testing platform for decentralized settings.

   Source
6. 2014Alere i influenza test receives FDA clearance

   The FDA cleared the Alere i Influenza A&B rapid molecular test, designed to differentiate influenza A and B in less than 15 minutes.

   Source
7. 2013Epocal acquisition is completed

   Alere completed its acquisition of Epocal, adding to its point-of-care diagnostics capabilities.

   Source
8. 2010The Alere brand is adopted

   Inverness Medical Innovations changed its name to Alere and began trading under the ALR ticker on the New York Stock Exchange.

   Source
9. 2010Alere CD4 analyser is launched

   Alere introduced a point-of-care analyser designed to provide absolute CD4 results for HIV patient management.

   Source
10. 2007Swiss Precision Diagnostics joint venture is formed

    Alere’s predecessor entered a consumer-diagnostics sales and marketing joint venture with Procter & Gamble.

    Source
11. 2004Clearblue Digital pregnancy test is launched

    The company launched Clearblue Digital, described in reference material as the first digital pregnancy test.

    Source
12. 2001Diabetes business is sold and Inverness Medical Innovations is separated

    The company sold its diabetes business to Johnson & Johnson and separated Inverness Medical Innovations as a new corporate entity.

    Source
13. 2000Name changes to Inverness Medical Technology

    SelfCare changed its corporate name to Inverness Medical Technology.

    Source
14. 1996SelfCare becomes publicly traded

    The company entered the public markets during its SelfCare period.

    Source
15. 1991SelfCare is founded

    Ron Zwanziger founded the company that would later become Alere, initially under the name SelfCare.

    Source

A global provider of rapid diagnostics designed to deliver laboratory-informed results closer to patients and healthcare professionals.

• Point-of-care diagnosticsMedical diagnostics

  Alere’s central business was a broad range of tests and instruments intended for use near the patient. These products served hospitals, clinics, pharmacies, physician offices, emergency departments, public-health programs, and other decentralized care locations. The value proposition was faster access to results and reduced dependence on centralized laboratory infrastructure.

• Alere iRapid molecular diagnostics2014

  The Alere i platform was designed to bring molecular testing into point-of-care environments. Its menu included influenza A and B testing, group A streptococcal testing, and respiratory syncytial virus testing. The platform emphasized short turnaround times suitable for clinical decisions during a patient visit.

• Alere CD4 analyserHIV and immunology diagnostics2010

  The Alere CD4 analyser was developed to provide absolute CD4 results at the point of care. It was intended to support HIV patient assessment and management, particularly in settings where access to conventional laboratory testing could be limited or delayed.

• Alere q HIV analyserMolecular diagnostics

  The Alere q HIV analyser was an automated nucleic-acid testing platform designed to bring molecular HIV testing closer to patients. Its compact, decentralized approach was aimed at healthcare settings that needed laboratory-style capabilities without a large central laboratory.

• Triage productsCardiometabolic and acute-care diagnostics

  The Triage range comprised point-of-care diagnostic products associated with cardiometabolic and acute-care testing. The products were part of Alere’s professional diagnostics portfolio and were also the subject of FDA manufacturing-process observations and a 2012 warning.

• Toxicology testingToxicology diagnostics

  Through acquisitions and internal operations, Alere developed a substantial toxicology business serving clinical, workplace, forensic, and related testing contexts. The portfolio included rapid tests and screening services for drugs of abuse and other toxicology applications.

• Clearblue Digital pregnancy testConsumer diagnostics2004

  Clearblue Digital was a consumer pregnancy-testing product associated with Alere’s consumer diagnostics activities and the Swiss Precision Diagnostics joint venture with Procter & Gamble. The product used a digital display to communicate the test result to consumers.

• 2009Consumer health information program recognition

  United States

  Alere received two awards in the sixteenth annual National Health Information program, which recognized consumer health information programs and materials in the United States.

  Outcome. The recognition highlighted Alere’s consumer-facing health information work, although the available reference does not identify the individual programs or award categories.

  Source
• 2007Swiss Precision Diagnostics consumer diagnostics venture

  International consumer healthcare markets

  Alere’s predecessor formed Swiss Precision Diagnostics with Procter & Gamble to support the sales and marketing of consumer diagnostic products, extending the company’s reach beyond professional point-of-care testing.

  Outcome. The venture became part of the company’s consumer diagnostics strategy, including pregnancy-testing products such as Clearblue.

  Source

• 2016Agree to Abbott acquisitionM&A

  Abbott sought to expand its diagnostics business and strengthen its position in point-of-care testing, while Alere faced strategic and operating pressures.

  What changed. Alere agreed to be acquired by Abbott Laboratories. Abbott later requested termination of the agreement, but Alere’s board rejected that request.

  Aftermath. The parties renegotiated the transaction, which ultimately closed in 2017 at a reduced value. Alere ceased to operate as an independent listed company.

  Transaction value. 5.8 billion USD announced value → 5.3 billion USD completed value (2016 announcement; completed October 3, 2017)

  Source
• 2015Divest Alere Health management activitiesStrategy

  Alere was concentrating its portfolio around diagnostics while reassessing businesses outside its core testing operations.

  What changed. The company divested its Alere Health management activities to Optum.

  Aftermath. The divestiture reduced Alere’s exposure to health-management services and sharpened its focus on diagnostic products and platforms.

  Source
• 2010Rebrand as AlereStrategy

  The company had expanded through multiple acquisitions and sought a clearer identity around diagnostics and point-of-care testing.

  What changed. Inverness Medical Innovations changed its corporate name to Alere and adopted the ALR trading symbol.

  Aftermath. The Alere name became the umbrella identity for the company’s professional, consumer, molecular, cardiometabolic, infectious-disease, and toxicology activities.

  Source

• 2016Investigation into possible Medicaid and Medicare fraudControversy

  The United States Department of Justice opened an investigation into Alere’s possible role in Medicaid and Medicare fraud. The supplied reference identifies the investigation but does not provide a final adjudication or settlement outcome.

  Source
• 2012FDA warning concerning Triage manufacturing processesControversy

  The Food and Drug Administration warned Alere over what it described as an inadequate response to earlier observations concerning the company’s manufacturing processes for Triage products. The available reference does not establish a specific patient-harm finding or final enforcement outcome.

  Source

• 2017Abbott completes acquisition of Alere

  Abbott completed its acquisition of Alere on October 3, ending Alere’s existence as an independent public company and integrating its operations into Abbott’s diagnostics business.

  M&A
  Source
• 2016Abbott announces agreement to acquire Alere

  Abbott Laboratories announced an agreement to acquire Alere, initiating a transaction that later became subject to disputes over whether the deal should proceed.

  M&A
  Source
• 2014Ron Zwanziger resigns as chief executive

  Ron Zwanziger left the chief executive role, and Chief Operating Officer Namal Nawana initially became interim CEO.

  Leadership change
  Source
• 2014Namal Nawana appointed permanent CEO

  Alere’s board appointed Namal Nawana as the company’s permanent chief executive after his interim appointment.

  Leadership change
  Source
• 2010Alere adopts its new corporate name

  The company formerly known as Inverness Medical Innovations changed its name to Alere and began trading under the ALR ticker on the New York Stock Exchange.

  OtherLeadership change
  Source

1. Alere
2. Abbott completes acquisition of Alere